Developmental Therapeutics Recent Publications
2023
- Associations between per- and polyfluoroalkyl substances, liver function, and daily alcohol consumption in a sample of U.S. adults.Ma X, Fisher JA, VoPham T, Vasiliou V, Jones RR. Environ Res. 2023 Oct 15; 2023 Jul 13. PMID: 37451576.
- Determinants of overall survival in patients with metastatic uveal melanoma.Demkowicz P, Pointdujour-Lim R, Miguez S, Lee Y, Jones BSCL, Barker CA, Bosenberg M, Abramson DH, Shoushtari AN, Kluger H, Francis JH, Sznol M, Bakhoum MF. Cancer. 2023 Oct 15; 2023 Jun 29. PMID: 37382208.
- Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities.AlAshqar A, Ghazarian M, Webster EM, Upadhyay A, Azodi M, Schwartz PE, Ratner E, Altwerger G. Gynecol Oncol Rep. 2023 Oct; 2023 Jul 10. PMID: 37636496.
- Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy?Lu BY, Goldberg SB. J Clin Oncol. 2023 Oct 1; 2023 Aug 21. PMID: 37603819.
- Bidirectional processes linking social determinants of health and pediatric sickle cell anemia management: A qualitative study.Long KA, Blakey AO, Amaro CM, Eilenberg JS, Brochier A, Garg A, Drainoni ML, Pashankar F, Esrick EB, Kavanagh PL. Pediatr Blood Cancer. 2023 Oct; 2023 Jul 20. PMID: 37470711.
- Against the Waves: Blocking the EB3-IP3 Interaction Inhibits Calcium Waves in the Lung Endothelium.Takyar SS. Am J Respir Cell Mol Biol. 2023 Oct. PMID: 37348847.
- Precision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?Farrell JJ, Robert ME, Lacy J. Clin Gastroenterol Hepatol. 2023 Oct; 2023 Jan 12. PMID: 36640803.
- Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.Wong SJ, Torres-Saavedra PA, Saba NF, Shenouda G, Bumpous JM, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant PA, Dunlap NE, Redman R, Stokes WA, Rudra S, Mell LK, Sacco AG, Spencer SA, Nabell L, Yao M, Cury FL, Mitchell DL, Jones CU, Firat S, Contessa JN, Galloway T, Currey A, Harris J, Curran WJ Jr, Le QT. JAMA Oncol. 2023 Sep 28; 2023 Sep 28. PMID: 37768670.
- Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC. JAMA Oncol. 2023 Sep 28; 2023 Sep 28. PMID: 37768658.
- Data Science-Enabled Palladium-Catalyzed Enantioselective Aryl-Carbonylation of Sulfonimidamides.van Dijk L, Haas BC, Lim NK, Clagg K, Dotson JJ, Treacy SM, Piechowicz KA, Roytman VA, Zhang H, Toste FD, Miller SJ, Gosselin F, Sigman MS. J Am Chem Soc. 2023 Sep 27; 2023 Sep 1. PMID: 37656964.
- Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P. Leukemia. 2023 Sep 26; 2023 Sep 26. PMID: 37752285.
- EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)-A Podcast Discussion Between Patients and Oncologists.Liu SV, Elkins IB, Feldman J, Goldberg SB. Oncol Ther. 2023 Sep 26; 2023 Sep 26. PMID: 37750968.
- Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.Badar T, Madanat YF, Zeidan AM. Future Oncol. 2023 Sep 26; 2023 Sep 26. PMID: 37750305.
- MicroRNA-1 protects the endothelium in acute lung injury.Korde A, Haslip M, Pednekar P, Khan A, Chioccioli M, Mehta S, Lopez-Giraldez F, Bermejo S, Rojas M, Dela Cruz C, Matthay MA, Pober JS, Pierce RW, Takyar SS. JCI Insight. 2023 Sep 22; 2023 Sep 22. PMID: 37737266.
- TNFα increases the degradation of pyruvate dehydrogenase kinase 4 by the Lon protease to support proinflammatory genes.Boutagy NE, Fowler JW, Grabinska KA, Cardone R, Sun Q, Vazquez KR, Whalen MB, Zhu X, Chakraborty R, Martin KA, Simons M, Romanoski CE, Kibbey RG, Sessa WC. Proc Natl Acad Sci U S A. 2023 Sep 19; 2023 Sep 11. PMID: 37695914.
- It could happen in your backyard.Strazzabosco M. Hepatology. 2023 Sep 18; 2023 Sep 18. PMID: 37722133.
- Multi-omics profiling reveals cellular pathways and functions regulated by ALDH1B1 in colon cancer cells.Wang Y, Popovic Z, Charkoftaki G, Garcia-Milian R, Lam TT, Thompson DC, Chen Y, Vasiliou V. Chem Biol Interact. 2023 Sep 15; 2023 Sep 15. PMID: 37716420.
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.Croucher PJP, Ridinger M, Becker PS, Lin TL, Silberman SL, Wang ES, Zeidan AM. Ann Hematol. 2023 Sep 13; 2023 Sep 13. PMID: 37702821.
- Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia.Podoltsev NA, Wang R, Shallis RM, Stempel JM, Di M, Neparidze N, Zeidan AM, Huntington SF, Giri S, Hull SC, Gore SD, Ma X. Cancer Med. 2023 Sep 13; 2023 Sep 13. PMID: 37702132.
- Reply to D. Wu et al.Herbst RS, Wu YL, Tsuboi M. J Clin Oncol. 2023 Sep 10; 2023 Jun 30. PMID: 37390374.
- Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. J Clin Oncol. 2023 Sep 10; 2023 Jun 28. PMID: 37379495.
- Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence meta-analysis to Estimate the Rate of low-yield Surgery.Paiella S, Secchettin E, Lionetto G, Archibugi L, Azzolina D, Casciani F, Simeone DM, Overbeek KA, Goggins M, Farrell J, Ponz de Leon Pisani R, Tridenti M, Corciulo MA, Malleo G, Arcidiacono PG, Falconi M, Gregori D, Bassi C, Salvia R, Capurso G. Ann Surg. 2023 Sep 8; 2023 Sep 8. PMID: 37681303.
- In vivo and in vitro efficacy of trastuzumab deruxtecan in uterine serous carcinoma.Mutlu L, Manavella DD, Bellone S, McNamara B, Harold JA, Mauricio D, Siegel ER, Buza N, Hui P, Hartwich TM, Yang-Hartwich Y, Demirkiran C, Verzosa MSZ, Altwerger G, Ratner ES, Huang GS, Clark M, Andikyan V, Azodi M, Dottino PR, Schwartz PE, Santin AD. Mol Cancer Ther. 2023 Sep 7; 2023 Sep 7. PMID: 37676984.
- Atezolizumab for Advanced Alveolar Soft Part Sarcoma.Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. N Engl J Med. 2023 Sep 7. PMID: 37672694.
- Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.Stockton S, Catalano P, Cohen SJ, Burtness BA, Mitchell EP, Dotan E, Lubner SJ, Kumar P, Mulcahy MF, Fisher GA, Crandall TL, Benson A. Oncologist. 2023 Sep 7. PMID: 37104870.
- Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. JCO Precis Oncol. 2023 Sep. PMID: 37677122.
- Reply to: Amniote metabolism and the evolution of endothermy.Wiemann J, Menéndez I, Crawford JM, Fabbri M, Gauthier JA, Hull PM, Norell MA, Briggs DEG. Nature. 2023 Sep. PMID: 37673991.
- Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Ettinger DS, Wood DE, Stevenson J, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hughes M. J Natl Compr Canc Netw. 2023 Sep. PMID: 37673108.
- 3D FRONSAC with PSF reconstruction.Rodriguez Y, Elsaid NMH, Keil B, Galiana G. J Magn Reson. 2023 Sep 1; 2023 Sep 1. PMID: 37672990.
- Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.Qureshi HM, Tabor JK, Pickens K, Lei H, Vasandani S, Jalal MI, Vetsa S, Elsamadicy A, Marianayagam N, Theriault BC, Fulbright RK, Qin R, Yan J, Jin L, O'Brien J, Morales-Valero SF, Moliterno J. J Neurooncol. 2023 Sep; 2023 Aug 25. PMID: 37624530.
- Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Lancet Haematol. 2023 Sep; 2023 Aug 9. PMID: 37572683.
- On the Ability of the N-O Bond to Support a Stable Stereogenic Axis: Peptide-Catalyzed Atroposelective N-Oxidation.Huth SE, Stone EA, Crotti S, Miller SJ. J Org Chem. 2023 Sep 1; 2023 Aug 10. PMID: 37561942.
- Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.Doroshow DB, Wei W, Mehrotra M, Sia D, Eder JP, Bindra R, Houldsworth J, LoRusso P, Walther Z. Cancer Invest. 2023 Sep; 2023 Aug 17. PMID: 37505929.
- The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors.Dougherty MW, Valdés-Mas R, Wernke KM, Gharaibeh RZ, Yang Y, Brant JO, Riva A, Muehlbauer M, Elinav E, Puschhof J, Herzon SB, Jobin C. Neoplasia. 2023 Sep; 2023 Jul 25. PMID: 37499275.
- Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.Kaulen LD, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann DC, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring JM, Brors B, Sahm F, Wick W. Acta Neuropathol. 2023 Sep; 2023 Jul 26. PMID: 37495858.
- Development of an orally bioavailable selective inhibitor of the menin-MLL.Zhong HJ, Wang W, Zhou W, Liang JX, Cheng YC, Ma DL, Leung CH. Genes Dis. 2023 Sep; 2022 Oct 18. PMID: 37492738.
- Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.Bhuta R, Shah R, Gell JJ, Poynter JN, Bagrodia A, Dicken BJ, Pashankar F, Frazier AL, Shaikh F. Pediatr Blood Cancer. 2023 Sep; 2023 Jul 14. PMID: 37449938.
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.Gelissen JH, Adjei NN, McNamara B, Mutlu L, Harold JA, Clark M, Altwerger G, Dottino PR, Huang GS, Santin AD, Azodi M, Ratner E, Schwartz PE, Andikyan V. Ann Surg Oncol. 2023 Sep; 2023 Jun 26. PMID: 37358686.
- Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, Fathi AT, Kuykendall AT, Zheng F, Walker C, Cheng L, Marando C, Savona MR. Clin Lymphoma Myeloma Leuk. 2023 Sep; 2023 May 15. PMID: 37290996.
- Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. J Thorac Oncol. 2023 Sep; 2023 May 24. PMID: 37236398.
- Humanized mouse liver reveals endothelial control of essential hepatic metabolic functions.Kaffe E, Roulis M, Zhao J, Qu R, Sefik E, Mirza H, Zhou J, Zheng Y, Charkoftaki G, Vasiliou V, Vatner DF, Mehal WZ, Yuval Kluger, Flavell RA. Cell. 2023 Aug 31; 2023 Aug 9. PMID: 37562401.
- CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?Su D, Kluger H, Weiss SA. Ann Transl Med. 2023 Aug 30; 2023 Mar 6. PMID: 37675335.
- Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution.Santinelli E, Pascale MR, Xie Z, Badar T, Stahl MF, Bewersdorf JP, Gurnari C, Zeidan AM. Blood Rev. 2023 Aug 29; 2023 Aug 29. PMID: 37679263.
- An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model.Charkoftaki G, Aalizadeh R, Santos-Neto A, Tan WY, Davidson EA, Nikolopoulou V, Wang Y, Thompson B, Furnary T, Chen Y, Wunder EA, Coppi A, Schulz W, Iwasaki A, Pierce RW, Cruz CSD, Desir GV, Kaminski N, Farhadian S, Veselkov K, Datta R, Campbell M, Thomaidis NS, Ko AI, Thompson DC, Vasiliou V. Hum Genomics. 2023 Aug 29; 2023 Aug 29. PMID: 37641126.
- Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.McNamara B, Chang Y, Goreshnik A, Santin AD. Int J Womens Health. 2023; 2023 Aug 28. PMID: 37663226.
- Computation of Absolute Binding Free Energies for Noncovalent Inhibitors with SARS-CoV-2 Main Protease.Ghahremanpour MM, Saar A, Tirado-Rives J, Jorgensen WL. J Chem Inf Model. 2023 Aug 28; 2023 Aug 10. PMID: 37561001.
- Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.Smalley I, Boire A, Brastianos P, Kluger HM, Hernando-Monge E, Forsyth PA, Ahmed KA, Smalley KSM, Ferguson S, Davies MA, Glitza Oliva IC. Pigment Cell Melanoma Res. 2023 Aug 25; 2023 Aug 25. PMID: 37622466.
- A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors.Carducci MA, Wang D, Habermehl C, Bödding M, Rohdich F, Lignet F, Duecker K, Karpenko O, Pudelko L, Gimmi C, LoRusso P. Cancer Res Commun. 2023 Aug; 2023 Aug 24. PMID: 37637935.
- Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J. N Engl J Med. 2023 Aug 24. PMID: 37611121.
- Progress on the Pharmacological Targeting of Janus Pseudokinases.Henry SP, Jorgensen WL. J Med Chem. 2023 Aug 24; 2023 Aug 14. PMID: 37578217.
- Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Blood Rev. 2023 Aug 19; 2023 Aug 19. PMID: 37704469.
- Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination.Suberi A, Grun MK, Mao T, Israelow B, Reschke M, Grundler J, Akhtar L, Lee T, Shin K, Piotrowski-Daspit AS, Homer RJ, Iwasaki A, Suh HW, Saltzman WM. Sci Transl Med. 2023 Aug 16; 2023 Aug 16. PMID: 37585505.
- Finding activity through rigidity: syntheses of natural products containing tricyclic bridgehead carbon centers.Xu Z, Li X, Rose JA, Herzon SB. Nat Prod Rep. 2023 Aug 16; 2023 Aug 16. PMID: 37140079.
- HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.McNamara B, Mutlu L, Greenman M, Harold J, Santin A. Cancers (Basel). 2023 Aug 14; 2023 Aug 14. PMID: 37627113.
- Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.Schrank TP, Kothari A, Weir WH, Stepp WH, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward MC, Wu D, Burtness B, Anderson KS, Baldwin AS, Yarbrough WG, Issaeva N. Proc Natl Acad Sci U S A. 2023 Aug 8; 2023 Jul 31. PMID: 37523561.
- The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, Davenport T, Teufel M, Li J, Lahmar M, Gounder MM. Cancer Discov. 2023 Aug 4. PMID: 37269344.
- A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1.Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MA, Muñoz-Couselo E, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez Cao M, Arance Fernandez A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, Kluger HM. Clin Cancer Res. 2023 Aug 3; 2023 Aug 3. PMID: 37535056.
- Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease.Fouda RT, Cherukury HM, Kiven SB, Garcia NR, Argueta DA, Velasco GJ, Gupta K, Roberts JD. Haematologica. 2023 Aug 3; 2023 Aug 3. PMID: 37534545.
- Costs of fall injuries in the STRIDE study: an economic evaluation of healthcare system heterogeneity and heterogeneity of treatment effect.Ganz DA, Gill TM, Reuben DB, Bhasin S, Latham NK, Peduzzi P, Greene EJ. Cost Eff Resour Alloc. 2023 Aug 2; 2023 Aug 2. PMID: 37533073.
- A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.Garralda E, Schram AM, Bedard PL, Schwartz GK, Yuen E, McNeely SC, Ribeiro S, Cunningham J, Wang Y, Urunuela A, Xu X, LoRusso P. Oncologist. 2023 Aug 2; 2023 Aug 2. PMID: 37531083.
- A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial.Malarkey M, Toscano AP, Bagheri MH, Solomon J, Machado LB, LoRusso P, Chen A, Folio LR, Goncalves PH. Heliyon. 2023 Aug; 2023 Jul 31. PMID: 37593628.
- Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586773.
- ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis.Mann JE, Lucca L, Austin MR, Merkin RD, Robert ME, Al Bawardy B, Raddassi K, Aizenbud L, Joshi NS, Hafler DA, Abraham C, Herold KC, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586769.
- Precise, pragmatic and inclusive: the modern era of oncology clinical trials.Grant MJ, Goldberg SB. Nat Med. 2023 Aug. PMID: 37524954.
- Synthesis of N-Acylsulfenamides from Amides and N-Thiosuccinimides.Liu JT, Brandes DS, Greenwood NS, Ellman JA. Synthesis (Stuttg). 2023 Aug; 2022 Dec 20. PMID: 37457378.
- Rational nanoparticle design: Optimization using insights from experiments and mathematical models.Richfield O, Piotrowski-Daspit AS, Shin K, Saltzman WM. J Control Release. 2023 Aug; 2023 Jul 22. PMID: 37442201.
- SREBP2 regulates the endothelial response to cytokines via direct transcriptional activation of KLF6.Fowler JWM, Boutagy NE, Zhang R, Horikami D, Whalen MB, Romanoski CE, Sessa WC. J Lipid Res. 2023 Aug; 2023 Jul 10. PMID: 37437844.
- Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Ann Hematol. 2023 Aug. PMID: 37341779.
- Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.McNamara B, Bellone S, Demirkiran C, Max Philipp Hartwich T, Santin AD. Gynecol Oncol Rep. 2023 Aug; 2023 Jun 3. PMID: 37325296.
- Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy.McNamara B, Bellone S, Demirkiran C, Hartwich TMP, Santin AD. Gynecol Oncol Rep. 2023 Aug; 2023 Jun 4. PMID: 37325293.
- Age-related reduction in trait anxiety: Behavioral and neural evidence of automaticity in negative facial emotion processing.Chaudhary S, Zhang S, Zhornitsky S, Chen Y, Chao HH, Li CR. Neuroimage. 2023 Aug 1; 2023 May 30. PMID: 37263454.
- Disparities in COVID-19 vaccine hesitancy among a diverse community-based sample in Connecticut, United States.Eger WH, Suttiratana SC, Herbst RL, Behringer H, Ibrahim E, Jones BA. Prev Med Rep. 2023 Aug; 2023 May 24. PMID: 37252068.
- Adjuvant chemotherapy does not improve outcome in children with ovarian immature teratoma: A comparative analysis of clinical trial data from the Malignant Germ Cell International Consortium.Vieira AGS, Puthenpura V, Krailo M, Fallahazad N, Brougham MFH, Murray MJ, Frazier AL, Lopes LF, Pashankar F. Pediatr Blood Cancer. 2023 Aug; 2023 May 26. PMID: 37243320.
- Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka JJ. Clin Cancer Res. 2023 Aug 1. PMID: 37233452.
- Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Cascone T, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Wu S, Ascierto ML, Elgeioushi N, Awad MM. J Thorac Oncol. 2023 Aug; 2023 May 4. PMID: 37146752.
- Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. J Clin Oncol. 2023 Aug 1; 2023 Mar 28. PMID: 36977289.
- Celastrol attenuates hepatitis C virus translation and inflammatory response in mice by suppressing heat shock protein 90β.Chen SR, Li ZQ, Xu J, Ding MY, Shan YM, Cheng YC, Zhang GX, Sun YW, Wang YQ, Wang Y. Acta Pharmacol Sin. 2023 Aug; 2023 Mar 7. PMID: 36882503.
- Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.Di M, Long JB, Kothari SK, Sethi T, Zeidan AM, Podoltsev NA, Shallis RM, Wang R, Ma X, Huntington SF. Haematologica. 2023 Aug 1; 2023 Aug 1. PMID: 36655436.
- Beyond In-hospital Mortality: Use of Postdischarge Quality-Metrics Provides a More Complete Picture of Older Adult Trauma Care.Zogg CK, Cooper Z, Peduzzi P, Falvey JR, Tinetti ME, Lichtman JH. Ann Surg. 2023 Aug 1; 2022 Sep 15. PMID: 36111845.
- Living Donor Liver Transplantation (LDLT) for Hepatocellular Carcinoma (HCC) within and Outside Traditional Selection Criteria: A Multicentric North American Experience.Ivanics T, Claasen MP, Samstein B, Emond JC, Fox AN, Pomfret E, Pomposelli J, Tabrizian P, Florman SS, Mehta N, Roberts JP, Emamaullee JA, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Quintini C, Nagai S, Abouljoud M, Olthoff KM, Hoteit MA, Heimbach J, Taner T, Liapakis AH, Mulligan DC, Sapisochin G, Halazun KJ. Ann Surg. 2023 Jul 31; 2023 Jul 31. PMID: 37522174.
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Lancet. 2023 Jul 29; 2023 Jun 10. PMID: 37311468.
- Catalytic Asymmetric Hydrogen Atom Transfer: Enantioselective Hydroamination of Alkenes.Hejna BG, Ganley JM, Shao H, Tian H, Ellefsen JD, Fastuca NJ, Houk KN, Miller SJ, Knowles RR. J Am Chem Soc. 2023 Jul 26; 2023 Jul 11. PMID: 37432783.
- Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.Wong S, Hamidi H, Costa LJ, Bekri S, Neparidze N, Vij R, Nielsen TG, Raval A, Sareen R, Wassner-Fritsch E, Cho HJ. Front Immunol. 2023; 2023 Jul 25. PMID: 37559718.
- Microvascular Decompression for Treatment of Simultaneous Arterial and Venous Conflict Causing Trigeminal Neuralgia: 2-Dimensional Operative Video.Morales-Valero SF, Tabor JK, Moliterno J. Oper Neurosurg (Hagerstown). 2023 Jul 25; 2023 Jul 25. PMID: 37499238.
- IL-7R licenses a population of epigenetically poised memory CD8(+) T cells with superior antitumor efficacy that are critical for melanoma memory.Micevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn HN, Sefik E, Cheung JF, Hornick NI, Aizenbud L, Joshi NS, Kluger H, Iwasaki A, Bosenberg MW, Flavell RA. Proc Natl Acad Sci U S A. 2023 Jul 25; 2023 Jul 17. PMID: 37459511.
- COVID-19 annual update: a narrative review.Biancolella M, Colona VL, Luzzatto L, Watt JL, Mattiuz G, Conticello SG, Kaminski N, Mehrian-Shai R, Ko AI, Gonsalves GS, Vasiliou V, Novelli G, Reichardt JKV. Hum Genomics. 2023 Jul 24; 2023 Jul 24. PMID: 37488607.
- Response to Kochan et al., 2023.Ehrlich BE, Vahdat L, DeCillis AP, Seidman A. Support Care Cancer. 2023 Jul 22; 2023 Jul 22. PMID: 37480366.
- Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.Wang Z, Muthusamy V, Petrylak DP, Anderson KS. NPJ Precis Oncol. 2023 Jul 21; 2023 Jul 21. PMID: 37479885.
- Combinatorial immunotherapy with agonistic CD40 activates dendritic cells to express IL12 and overcomes PD-1 resistance.Krykbaeva I, Bridges K, Damsky W, Pizzurro GA, Alexander AF, McGeary MK, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss SA, Olino K, Kaech SM, Kluger HM, Miller-Jensen K, Bosenberg M. Cancer Immunol Res. 2023 Jul 21; 2023 Jul 21. PMID: 37478171.
- Computational Prediction of the Interaction of Ivermectin with Fibrinogen.Vottero P, Tavernini S, Santin AD, Scheim DE, Tuszynski JA, Aminpour M. Int J Mol Sci. 2023 Jul 14; 2023 Jul 14. PMID: 37511206.
- Considerations for Drug Development in Myelodysplastic Syndromes.Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS. Clin Cancer Res. 2023 Jul 14. PMID: 36688922.
- Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL. N Engl J Med. 2023 Jul 13; 2023 Jun 4. PMID: 37272535.
- Bone Mass Changes Following Percutaneous Radiofrequency Ablation, Osteoplasty, Reinforcement, and Internal Fixation of Periacetabular Osteolytic Metastases.Jiang W, Caruana DL, Dussik CM, Conway D, Latich I, Chapiro J, Lindskog DM, Friedlaender GE, Lee FY. J Clin Med. 2023 Jul 11; 2023 Jul 11. PMID: 37510728.
- Acetate controls endothelial-to-mesenchymal transition.Zhu X, Wang Y, Soaita I, Lee HW, Bae H, Boutagy N, Bostwick A, Zhang RM, Bowman C, Xu Y, Trefely S, Chen Y, Qin L, Sessa W, Tellides G, Jang C, Snyder NW, Yu L, Arany Z, Simons M. Cell Metab. 2023 Jul 11; 2023 Jun 15. PMID: 37327791.
- Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.Shallis RM, Wang R, Zeidan AM, Huntington SF, Neparidze N, Stempel JM, Mendez LM, Di M, Ma X, Podoltsev NA. Blood Adv. 2023 Jul 11. PMID: 36939371.
- A Th17 cell-intrinsic glutathione/mitochondrial-IL-22 axis protects against intestinal inflammation.Bonetti L, Horkova V, Longworth J, Guerra L, Kurniawan H, Franchina DG, Soriano-Baguet L, Grusdat M, Spath S, Koncina E, Ewen A, Binsfeld C, Verschueren C, Gérardy JJ, Kobayashi T, Dostert C, Farinelle S, Härm J, Chen Y, Harris IS, Lang PA, Vasiliou V, Waisman A, Letellier E, Becher B, Mittelbronn M, Brenner D. bioRxiv. 2023 Jul 7; 2023 Jul 7. PMID: 37489135.
- Alzheimer's disease: using gene/protein network machine learning for molecule discovery in olive oil.Rita L, Neumann NR, Laponogov I, Gonzalez G, Veselkov D, Pratico D, Aalizadeh R, Thomaidis NS, Thompson DC, Vasiliou V, Veselkov K. Hum Genomics. 2023 Jul 7; 2023 Jul 7. PMID: 37420280.
- Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Cancer Discov. 2023 Jul 7. PMID: 37068173.
- Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases.Rusheen J, Clune J, Ariyan S, Baumann R, Kluger H, Olino K, Weiss S. Front Oncol. 2023; 2023 Jul 5. PMID: 37476373.
- Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations.George TJ, Lin TL, Adrales Bentz T, Grant S, Houston CM, Nashawati MA, Pappu B, Peck H, Zafirovski A, Kerstann K, LoRusso P, Schnatterly A, Hofacker J, Cameron K, Honeycutt H, Werner TL. JNCI Cancer Spectr. 2023 Jul 3. PMID: 37467065.